Healthcare
Korro Bio, Inc.(KRRO)
Live Price
Offline$12.99
+17.56% today
1Y Change
+15.33%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $130.00M
- Revenue Growth
- +181.5%
- EPS Growth
- -33.2%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Korro Bio, Inc. (KRRO) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $12.99 and up 15.3% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +181.5%, EPS growth of -33.2%, a dividend yield of 0.0%. What stands out right now is revenue +181.5%, EPS -33.2%, free cash flow -1.4% with operating margin -1366.4% and ROIC -83.8%. Valuation already assumes a fairly strong business story at price/sales 20.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KRRO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+181.5% vs +7.6% peer median
Operating Margin
Below sector median
-1366.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 7, 2026 with an EPS surprise of -5.6%.
The operating picture looks softer than before
Revenue is at +181.5% and EPS is at -33.2%, with operating margin around -1366.4%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 11, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -32.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | -5.6% | -6.5% | -14.0% | -16.8% |
2026 Mar 12, 2026 | -175.7% | +11.3% | -3.8% | +10.3% |
2025 Nov 12, 2025 | +26.4% | -79.3% | -79.6% | -74.9% |
Benchmark Edge
KRRO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KRRO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KRRO Max Drawdown
-89.72%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KRRO and SPY.
Company Overview
Korro Bio, Inc.
NASDAQ Capital Market
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
- Leadership
- Ram Aiyar
- IPO Date
- Oct 3, 2019
- Employees
- 112
- Street Address
- One Kendall Square
- Mailing
- Cambridge, MA, 02139-1562
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 781-315-4600
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 20.0
- Price/Book
- 2.5
Growth
- Revenue
- +181.5%
- EPS
- -33.2%
- Free Cash Flow
- -1.4%
Profitability
- Gross Margin
- 89.8%
- Operating Margin
- -1366.4%
- Net Margin
- -1834.5%
- ROE
- -115.9%
- ROIC
- -83.8%
Balance Sheet
- Debt/Equity
- 0.85
- Current Ratio
- 6.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.